EAM Investors LLC bought a new stake in Catalent, Inc. (NYSE:CTLT) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 61,148 shares of the company’s stock, valued at approximately $2,441,000.
Other hedge funds have also modified their holdings of the company. Acrospire Investment Management LLC boosted its holdings in shares of Catalent by 72.2% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock valued at $109,000 after purchasing an additional 1,300 shares in the last quarter. Quantbot Technologies LP boosted its holdings in shares of Catalent by 110.7% in the 2nd quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock valued at $120,000 after purchasing an additional 1,804 shares in the last quarter. Fortaleza Asset Management Inc. acquired a new stake in shares of Catalent in the 3rd quarter valued at $164,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Catalent by 12.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock valued at $177,000 after purchasing an additional 559 shares in the last quarter. Finally, Advisor Group Inc. boosted its holdings in shares of Catalent by 1.3% in the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock valued at $180,000 after purchasing an additional 65 shares in the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.
In other news, SVP Christine Dolan sold 1,594 shares of the stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total value of $61,767.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.70% of the stock is currently owned by corporate insiders.
A number of brokerages have weighed in on CTLT. ValuEngine downgraded Catalent from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. BidaskClub downgraded Catalent from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Catalent in a report on Monday, October 23rd. Wells Fargo & Company raised their target price on Catalent from $39.00 to $43.00 and gave the company an “outperform” rating in a report on Wednesday, September 20th. Finally, Bank of America Corporation reaffirmed a “buy” rating and issued a $45.00 target price (up previously from $40.00) on shares of Catalent in a report on Wednesday, September 20th. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Catalent has an average rating of “Buy” and a consensus price target of $42.11.
Shares of Catalent, Inc. (NYSE:CTLT) traded up $0.41 on Wednesday, hitting $38.91. The stock had a trading volume of 798,900 shares, compared to its average volume of 917,860. Catalent, Inc. has a one year low of $22.94 and a one year high of $43.39. The company has a market cap of $5,115.09, a PE ratio of 26.92, a price-to-earnings-growth ratio of 2.47 and a beta of 1.49. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01.
Catalent (NYSE:CTLT) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.21 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $490.75 million. During the same period in the prior year, the company earned $0.16 EPS. Catalent’s revenue was up 23.0% compared to the same quarter last year. research analysts anticipate that Catalent, Inc. will post 1.46 earnings per share for the current fiscal year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.